Ascendis embarks on R750m rights issue

Ascendis Health is embarking on a R750-million rights issue to settle much of the deferred vendor consideration payment outstanding from the 2016 acquisition of Cyprus-based pharmaceutical manufacturer Remedica. The group acquired Remedica for €260-million, which included a deferred payment of €90-million to be settled within three years of the conclusion of the transaction.